Auris Medical Holding AG Company Profile (NASDAQ:EARS)

About Auris Medical Holding AG

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EARS
  • CUSIP:
Key Metrics:
  • Previous Close: $0.92
  • 50 Day Moving Average: $1.11
  • 200 Day Moving Average: $1.49
  • 52-Week Range: $0.84 - $5.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.13
  • P/E Growth: 0.00
  • Market Cap: $32.27M
  • Outstanding Shares: 34,329,000
  • Beta: 1.13
Profitability:
  • Return on Equity: -96.60%
  • Return on Assets: -70.59%
Debt:
  • Debt-to-Equity Ratio: 0.55%
  • Current Ratio: 4.75%
  • Quick Ratio: 4.75%
Additional Links:
Companies Related to Auris Medical Holding AG:

Analyst Ratings

Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $10.33 (999.29% upside)

Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetDetails
11/11/2016JMP SecuritiesReiterated RatingHoldView Rating Details
8/19/2016Needham & Company LLCBoost Price TargetBuy$5.00 -> $11.00View Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00View Rating Details
6/10/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017        
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
5/11/2016Q116($0.23)($0.27)ViewListenView Earnings Details
3/14/2016Q415($0.28)($0.16)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.15)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.35)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014($0.34)($0.27)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $-0.83 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.29)($0.22)($0.25)
Q2 20163($0.33)($0.25)($0.28)
Q3 20162($0.29)($0.26)($0.28)
Q4 20162($0.31)($0.22)($0.27)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
DateHeadline
News IconPrice Target Review on Auris Medical Holding AG (NASDAQ:EARS) - Rockville Register (NASDAQ:EARS)
rockvilleregister.com - February 24 at 5:31 PM
streetinsider.com logoAuris Medical Holding (EARS) Announces FDA Fast Track Status for AM-111 - StreetInsider.com (NASDAQ:EARS)
www.streetinsider.com - February 24 at 5:31 PM
seekingalpha.com logoAuris Medical's AM-111 Fast Track'd in U.S. for inner ear hearing loss; shares up 13% premarket (NASDAQ:EARS)
seekingalpha.com - February 24 at 11:43 AM
feeds.benzinga.com logoAuris Medical Receives FDA Fast Track Designation for AM-111 in Acute Sensorineural Hearing Loss (NASDAQ:EARS)
feeds.benzinga.com - February 24 at 8:12 AM
News IconAuris Medical Announces Closing of $10 Million Public Offering (Auris Medical Holding AG) (NASDAQ:EARS)
www.newsoneplace.com - February 22 at 10:09 PM
News IconAuris Medical Holding AG EARS Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:EARS)
www.bioportfolio.com - February 22 at 10:09 PM
globenewswire.com logoAuris Medical and King's College London Extend Tinnitus Collaboration - GlobeNewswire (press release) (NASDAQ:EARS)
globenewswire.com - February 22 at 5:09 PM
finance.yahoo.com logoAuris Medical and King's College London Extend Tinnitus Collaboration (NASDAQ:EARS)
finance.yahoo.com - February 22 at 5:09 PM
finance.yahoo.com logoAuris Medical Announces Closing of $10 Million Public Offering (NASDAQ:EARS)
finance.yahoo.com - February 22 at 7:08 AM
News IconWalder Wyss advises Auris Medical on Nasdaq IPO (NASDAQ:EARS)
www.thelawyer.com - February 20 at 11:26 AM
reuters.com logoBRIEF-Empery Asset Management reports 5.64 pct passive stake in Auris Medical (NASDAQ:EARS)
in.reuters.com - February 17 at 6:35 PM
seekingalpha.com logoAuris prices equity offering; shares down 20% premarket (NASDAQ:EARS)
seekingalpha.com - February 16 at 8:38 PM
us.rd.yahoo.com logoAuris Medical Announces Pricing of $10 Million Public Offering (NASDAQ:EARS)
us.rd.yahoo.com - February 16 at 8:38 PM
streetinsider.com logoAuris Medical Holding (EARS) Prices 10M Shares and Warrants at $0.70/Share - StreetInsider.com (NASDAQ:EARS)
www.streetinsider.com - February 16 at 3:38 PM
finance.yahoo.com logo4:02 pm Auris Medical announces that it is offering to sell common shares and warrants to purchase its common shares in an underwritten public offering; size not disclosed (NASDAQ:EARS)
finance.yahoo.com - February 14 at 10:46 PM
streetinsider.com logoAuris Medical Holding (EARS) Plans Offering of Common Shares and Warrants (NASDAQ:EARS)
www.streetinsider.com - February 14 at 5:46 PM
streetinsider.com logoAuris Medical Holding (EARS) Plans Offering of Common Shares and Warrants - StreetInsider.com (NASDAQ:EARS)
www.streetinsider.com - February 14 at 5:46 PM
finance.yahoo.com logoAuris Medical Announces Proposed Public Offering of Common Shares and Warrants (NASDAQ:EARS)
finance.yahoo.com - February 14 at 5:46 PM
finance.yahoo.com logoAuris (EARS) Expands Pipeline with Intranasal Betahistine (NASDAQ:EARS)
finance.yahoo.com - February 14 at 3:38 AM
News IconShares Escalate Higher Mid-Session: Auris Medical Holding AG (NASDAQ:EARS) - Aiken Advocate (NASDAQ:EARS)
aikenadvocate.com - February 6 at 4:55 PM
finance.yahoo.com logoBlog Coverage Auris Medical Expands Clinical Development Pipeline for Treatment of Meniere's Disease and Vestibular Vertigo (NASDAQ:EARS)
finance.yahoo.com - February 6 at 8:51 AM
finance.yahoo.com logoAuris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's ... - Yahoo Finance (NASDAQ:EARS)
finance.yahoo.com - February 4 at 10:00 PM
seekingalpha.com logoAuris adds third clinical-stage development program - intranasal betahistine for Meniere's and vestibular vertigo (NASDAQ:EARS)
seekingalpha.com - February 3 at 5:14 PM
reuters.com logoBRIEF-Auris Medical expands clinical development pipeline for vertigo treatment (NASDAQ:EARS)
www.reuters.com - February 3 at 5:14 PM
nasdaq.com logoAuris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere''s Disease and Vestibular Vertigo (NASDAQ:EARS)
www.nasdaq.com - February 3 at 5:14 PM
feeds.benzinga.com logoAuris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo (NASDAQ:EARS)
feeds.benzinga.com - February 3 at 6:39 AM
News IconTrading Radar: Checking Technicals for Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - February 3 at 3:22 AM
finance.yahoo.com logoAuris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow, February 3, 2017 - Yahoo Finance (NASDAQ:EARS)
finance.yahoo.com - February 3 at 3:22 AM
us.rd.yahoo.com logoAuris Medical to Announce Business Update and Host Conference Call and Webcast Tomorrow, February 3, 2017 (NASDAQ:EARS)
us.rd.yahoo.com - February 2 at 5:21 PM
News IconReviewing Individual Broker Targets Of Auris Medical Holding AG (EARS) - NewsDen (NASDAQ:EARS)
newsden.net - January 31 at 4:43 AM
News IconNarrowing in on Trading Indicators for Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - January 31 at 4:43 AM
News IconSell-side Taking Aim at Shares of Auris Medical Holding AG (NASDAQ:EARS) - Aiken Advocate (NASDAQ:EARS)
aikenadvocate.com - January 30 at 5:46 PM
News IconOff To a Slow Start in The New Year, Stock Looks For a Turnaround: Auris Medical Holding AG (NASDAQ:EARS) - Aiken Advocate (NASDAQ:EARS)
aikenadvocate.com - January 29 at 3:12 AM
News IconTinnitus – Therapeutics & Drug Profile Pipeline Review, H2 2016 (NASDAQ:EARS)
empowerednews.net - January 27 at 11:31 PM
News IconADX Watch on Shares of Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - January 27 at 6:30 PM
streetinsider.com logoAuris Medical Holding (EARS) Says it Resumed Enrollment in TACTT3 Phase 3 Trial of Keyzilen (NASDAQ:EARS)
www.streetinsider.com - January 26 at 11:09 PM
us.rd.yahoo.com logo8:04 am Auris Medical resumes patient enrollment in the TACTT3 Phase 3 trial of Keyzilen (AM-101) in acute and post-acute inner ear tinnitus (NASDAQ:EARS)
us.rd.yahoo.com - January 26 at 11:09 PM
News IconBrokers Release Average Price Target Of 9.25 On Auris Medical Holding AG (EARS) - UK Market News (NASDAQ:EARS)
www.ukmarketnews.co.uk - January 26 at 6:09 PM
News IconStock Spotter: Review on Technical Levels for Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - January 26 at 6:09 PM
News IconStock Seesawing as Volatility Sweeps in on Auris Medical Holding AG (NASDAQ:EARS) - Wall Street Beacon (NASDAQ:EARS)
wsbeacon.com - January 26 at 6:09 PM
streetinsider.com logoAuris Medical Holding (EARS) Says it Resumed Enrollment in TACTT3 Phase 3 Trial of Keyzilen - StreetInsider.com (NASDAQ:EARS)
www.streetinsider.com - January 26 at 6:09 PM
finance.yahoo.com logoAuris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus (NASDAQ:EARS)
finance.yahoo.com - January 26 at 6:09 PM
News IconBargain Hunter's Delight: What's the Latest on Auris Medical Holding ... - Prospect Journal (NASDAQ:EARS)
prospectjournal.com - January 25 at 11:08 PM
News IconFocus on RSI and CCI Levels: Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - January 25 at 6:05 PM
kcregister.com logoStocks Alert: Lowe's Companies, Inc. (NYSE:LOW), Auris Medical Holding AG (NASDAQ:EARS), Xcel Energy Inc ... - KC Register (NASDAQ:EARS)
www.kcregister.com - January 24 at 5:31 PM
News IconAnalysts Take: Auris Medical Holding AG (NASDAQ:EARS) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:EARS)
aikenadvocate.com - January 24 at 5:31 PM
investornewswire.com logoSentiments And Ratings Alert: Auris Medical Holding AG (NASDAQ:EARS) - Investor Newswire (NASDAQ:EARS)
www.investornewswire.com - January 22 at 2:52 AM
News IconCurious Investors Should Take a Look at This Small Cap Stock: Auris Medical Holding AG (NASDAQ:EARS) - Prospect Journal (NASDAQ:EARS)
prospectjournal.com - January 18 at 10:16 PM
News IconCheck on Average Directional Index for Auris Medical Holding Ag (EARS) - Sherwood Daily (NASDAQ:EARS)
sherwooddaily.com - January 18 at 10:16 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Auris Medical Holding AG (NASDAQ:EARS) - Wall Street Beacon (NASDAQ:EARS)
wsbeacon.com - January 18 at 10:16 PM

Social

What is Auris Medical Holding AG's stock symbol?

Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."

Where is Auris Medical Holding AG's stock going? Where will Auris Medical Holding AG's stock price be in 2017?

4 analysts have issued 1 year price objectives for Auris Medical Holding AG's shares. Their predictions range from $8.00 to $12.00. On average, they expect Auris Medical Holding AG's stock price to reach $10.33 in the next year.

When will Auris Medical Holding AG announce their earnings?

Auris Medical Holding AG is scheduled to release their next quarterly earnings announcement on Monday, March, 13th 2017.

How do I buy Auris Medical Holding AG stock?

Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Auris Medical Holding AG stock cost?

One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.94.

Auris Medical Holding AG (NASDAQ:EARS) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Earnings History Chart

Earnings by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Dividend History Chart

Dividend Payments by Quarter for Auris Medical Holding AG (NASDAQ:EARS)

Last Updated on 2/25/2017 by MarketBeat.com Staff